• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Philips to acquire Intact Vascular for $275M

Philips to acquire Intact Vascular for $275M

August 27, 2020 By Sean Whooley

Royal Philips (NYSE:PHG) announced today that it agreed to acquire Intact Vascular in a deal worth approximately $275 million upfront.

Wayne, Pa.-based Intact Vascular makes the Tack specialized implantable device for treating peripheral artery disease (PAD). The Tack endovascular system reinforces standard and drug-coated balloon PAD treatment results as a first-of-its-kind, minimal-metal, dissection repair device for treating peripheral arterial dissections after balloon angioplasty in above-the-knee and below-the-knee interventions.

Tack leaves less metal behind when compared to stents, preserving future treatment options and limbs while also offering a solution for repairing dissections and optimizing post-angioplasty outcomes, according to a news release.

Philips’ acquisition is worth the $275 million upfront with deferred payments for which the company expects to recognize a provision of $85 million upon the completion of the transaction. Intact Vascular will join Philip’s image-guided therapy business.

“Acquiring Intact Vascular will expand our portfolio of minimally invasive therapy options for peripheral artery disease with the Tack endovascular system, a much-needed implant that effectively restores blood flow in small limb vessels, promotes healing and preserves limbs,” Philips senior VP & GM of image-guided therapy devices Chris Landon said in the release. “Through the integration of our interventional imaging systems and diagnostic and therapeutic devices, we will be able to provide clinicians with a complete procedural solution to optimize the treatment of patients with this disease.”

“We are excited about the strategic fit between our team, expertise and unique therapeutic device, and Philips’ image-guided therapy business,” added Intact Vascular president & CEO Bruce Shook. “We share the same vision of complete procedural solutions to improve existing procedures and expand treatment options. We look forward to completing the transaction and working closely with Philips on a seamless transition.”

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Imaging, Mergers & Acquisitions, Surgical, Vascular Tagged With: Intact Vascular, Philips

More recent news

  • Medtronic earns CE mark for redo TAVI procedure
  • Natus Neuro launches BrainWatch AI-driven, point-of-care EEG
  • Boston Scientific has positive real-world Acurate Prime TAVI data
  • Johnson & Johnson MedTech launches ultrasound catheter for imaging in cardiac ablation procedures
  • Onward reports more successful BCI implants

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy